Moderna Plans to Deliver Up to 3 Billion COVID-19 Vaccine Doses in 2022
Moderna said it plans to produce up to 3 billion doses of its messenger RNA-based COVID-19 vaccine globally in 2022, including booster shots against viral variants and pediatric vaccines.
The company said it aims to double drug substance manufacturing at the Lonza facility in Visp, Switzerland, and more than double substance manufacturing, formulation and fill-and-finish activities at the Rovi facility in Madrid, Spain.
It also plans to increase drug substance manufacturing across its U.S. facilities by 50 percent. The company previously announced manufacturing pacts with Catalent (DID, April 7) and Sanofi (DID, April 27) to bolster U.S. vaccine production.
The company has committed to supply 200 million doses to the U.S. by the end of July and has increased its global supply forecast to 1 billion doses for 2021. It has also agreed to supply the EU 310 million doses in 2021 with an option for an additional 150 million doses in 2022 (DID, Feb. 18).
“We believe that there will continue to be significant need for our mRNA COVID-19 vaccine and our variant booster candidates into 2022 and 2023,” said Moderna CEO Stéphane Bancel. — Jason Scott